US5776093A
(en)
*
|
1985-07-05 |
1998-07-07 |
Immunomedics, Inc. |
Method for imaging and treating organs and tissues
|
IE914075A1
(en)
*
|
1990-11-23 |
1992-06-03 |
Gen Hospital Corp |
Inhibition of cell adhesion protein-carbohydrate¹interactions
|
US5401489A
(en)
*
|
1991-05-01 |
1995-03-28 |
University Of New Mexico |
Biomodulators as universal imaging agents
|
US5364612A
(en)
*
|
1991-05-06 |
1994-11-15 |
Immunomedics, Inc. |
Detection of cardiovascular lesions
|
US5919455A
(en)
*
|
1993-10-27 |
1999-07-06 |
Enzon, Inc. |
Non-antigenic branched polymer conjugates
|
US5888773A
(en)
*
|
1994-08-17 |
1999-03-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of producing single-chain Fv molecules
|
US5559099A
(en)
*
|
1994-09-08 |
1996-09-24 |
Genvec, Inc. |
Penton base protein and methods of using same
|
US6465253B1
(en)
|
1994-09-08 |
2002-10-15 |
Genvec, Inc. |
Vectors and methods for gene transfer to cells
|
US5846782A
(en)
|
1995-11-28 |
1998-12-08 |
Genvec, Inc. |
Targeting adenovirus with use of constrained peptide motifs
|
US5545553A
(en)
*
|
1994-09-26 |
1996-08-13 |
The Rockefeller University |
Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
|
US5874540A
(en)
|
1994-10-05 |
1999-02-23 |
Immunomedics, Inc. |
CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
|
SE503711C2
(sv)
*
|
1994-12-14 |
1996-08-12 |
Medicarb Ab |
Flerstegsförfarande för beläggning av en intraokulär lins
|
US5770442A
(en)
*
|
1995-02-21 |
1998-06-23 |
Cornell Research Foundation, Inc. |
Chimeric adenoviral fiber protein and methods of using same
|
US6127525A
(en)
*
|
1995-02-21 |
2000-10-03 |
Cornell Research Foundation, Inc. |
Chimeric adenoviral coat protein and methods of using same
|
US6331273B1
(en)
|
1995-04-25 |
2001-12-18 |
Discovery Partners International |
Remotely programmable matrices with memories
|
US5751629A
(en)
|
1995-04-25 |
1998-05-12 |
Irori |
Remotely programmable matrices with memories
|
US6017496A
(en)
|
1995-06-07 |
2000-01-25 |
Irori |
Matrices with memories and uses thereof
|
US6329139B1
(en)
|
1995-04-25 |
2001-12-11 |
Discovery Partners International |
Automated sorting system for matrices with memory
|
US5874214A
(en)
|
1995-04-25 |
1999-02-23 |
Irori |
Remotely programmable matrices with memories
|
US6416714B1
(en)
*
|
1995-04-25 |
2002-07-09 |
Discovery Partners International, Inc. |
Remotely programmable matrices with memories
|
US6783980B2
(en)
*
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
DE69633565T3
(de)
|
1995-06-15 |
2013-01-17 |
Crucell Holland B.V. |
Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
|
AU702975B2
(en)
*
|
1995-09-22 |
1999-03-11 |
Immunomedics Inc. |
Recombinant proteins having multiple disulfide bonds and thiol-substituted conjugates thereof
|
WO1997023237A1
(en)
|
1995-12-22 |
1997-07-03 |
Immunomedics, Inc. |
Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
|
US6441025B2
(en)
*
|
1996-03-12 |
2002-08-27 |
Pg-Txl Company, L.P. |
Water soluble paclitaxel derivatives
|
WO1997034632A1
(en)
*
|
1996-03-20 |
1997-09-25 |
Immunomedics, Inc. |
Glycosylated humanized b-cell specific antibodies
|
US6730300B2
(en)
|
1996-03-20 |
2004-05-04 |
Immunomedics, Inc. |
Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
|
US5891506A
(en)
*
|
1996-08-09 |
1999-04-06 |
Medtronic, Inc. |
Oxidative method for attachment of glycoproteins or glycopeptides to surfaces of medical devices
|
JP4503706B2
(ja)
*
|
1996-06-07 |
2010-07-14 |
ポニアード ファーマシューティカルズ,インコーポレイティド |
グリコシル化が改質されたヒト化抗体
|
US5861308A
(en)
*
|
1996-08-21 |
1999-01-19 |
Ludwig Institute For Cancer Research |
Isolated nucleic acids associated with T cell activation and uses thereof
|
US6136274A
(en)
*
|
1996-10-07 |
2000-10-24 |
Irori |
Matrices with memories in automated drug discovery and units therefor
|
US6759509B1
(en)
|
1996-11-05 |
2004-07-06 |
Bristol-Myers Squibb Company |
Branched peptide linkers
|
EP0941120A4
(de)
*
|
1996-11-05 |
2004-08-18 |
Bristol Myers Squibb Co |
Verzweigte peptidlinker
|
US5816259A
(en)
*
|
1997-01-13 |
1998-10-06 |
Rose; Samuel |
Method for the diagnosis and treatment of cancer by the accumulation of radioactive precipitates in targeted cells
|
DE69840723D1
(de)
*
|
1997-02-11 |
2009-05-20 |
Immunomedics Inc |
Stimulation einer immunantwort durch antikörper, welche mit dem alpha-galaktosylepitop markiert sind
|
US7122636B1
(en)
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
EP0968291B1
(de)
|
1997-02-21 |
2004-01-28 |
Genentech, Inc. |
Antikörperfragment-polymerkonjugate
|
US6306393B1
(en)
*
|
1997-03-24 |
2001-10-23 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
US6183744B1
(en)
|
1997-03-24 |
2001-02-06 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
US6004529A
(en)
*
|
1997-04-11 |
1999-12-21 |
Nycomed Imaging As |
Chelating agents
|
AU7266898A
(en)
|
1997-04-30 |
1998-11-24 |
Enzon, Inc. |
Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
|
US20040009166A1
(en)
*
|
1997-04-30 |
2004-01-15 |
Filpula David R. |
Single chain antigen-binding polypeptides for polymer conjugation
|
US6673538B1
(en)
|
1997-07-25 |
2004-01-06 |
The Trustees Of Boston University |
Methods and compositions for designing vaccines
|
WO1999005325A1
(en)
|
1997-07-25 |
1999-02-04 |
The Trustees Of Boston University |
Methods and compositions for determining species of bacteria and fungi
|
US6953675B2
(en)
*
|
1997-11-06 |
2005-10-11 |
Immunomedics, Inc. |
Landscaped antibodies and antibody fragments for clinical use
|
US6458355B1
(en)
|
1998-01-22 |
2002-10-01 |
Genentech, Inc. |
Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
|
US6468532B1
(en)
|
1998-01-22 |
2002-10-22 |
Genentech, Inc. |
Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
|
US7005504B2
(en)
|
1998-01-22 |
2006-02-28 |
Genentech, Inc. |
Antibody fragment-peg conjugates
|
WO1999055365A1
(en)
|
1998-04-30 |
1999-11-04 |
Cornell Research Foundation, Inc. |
Adenoviral vectors with tandem fiber proteins
|
US6962702B2
(en)
|
1998-06-22 |
2005-11-08 |
Immunomedics Inc. |
Production and use of novel peptide-based agents for use with bi-specific antibodies
|
ATE407941T1
(de)
*
|
1998-07-02 |
2008-09-15 |
Univ Toronto |
Mit einer kohlenhydratgruppe chemisch modifizierte proteine
|
US20040043489A1
(en)
*
|
1998-07-08 |
2004-03-04 |
Menzo Havenga |
Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
|
US20030017138A1
(en)
*
|
1998-07-08 |
2003-01-23 |
Menzo Havenga |
Chimeric adenoviruses
|
JP2002524108A
(ja)
|
1998-07-28 |
2002-08-06 |
インナーダイン, インコーポレイテッド |
吸収性近接照射療法および化学療法送達デバイスならびに方法
|
WO2000015823A1
(en)
|
1998-09-11 |
2000-03-23 |
Genvec, Inc. |
Alternatively targeted adenovirus
|
US6333396B1
(en)
|
1998-10-20 |
2001-12-25 |
Enzon, Inc. |
Method for targeted delivery of nucleic acids
|
US6929946B1
(en)
*
|
1998-11-20 |
2005-08-16 |
Crucell Holland B.V. |
Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
|
US20030099629A1
(en)
*
|
1999-03-11 |
2003-05-29 |
Immunomedics, Inc. |
Recombinant onconase and chemical conjugates and fusion proteins of recombinant onconase
|
US8119101B2
(en)
*
|
1999-05-10 |
2012-02-21 |
The Ohio State University |
Anti-CD74 immunoconjugates and methods of use
|
US8383081B2
(en)
|
1999-05-10 |
2013-02-26 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods of use
|
US7829064B2
(en)
*
|
1999-05-10 |
2010-11-09 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods
|
US20050232900A1
(en)
*
|
1999-05-18 |
2005-10-20 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
US6492169B1
(en)
*
|
1999-05-18 |
2002-12-10 |
Crucell Holland, B.V. |
Complementing cell lines
|
US6913922B1
(en)
*
|
1999-05-18 |
2005-07-05 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
US7468181B2
(en)
*
|
2002-04-25 |
2008-12-23 |
Crucell Holland B.V. |
Means and methods for the production of adenovirus vectors
|
US7297478B1
(en)
|
2000-09-22 |
2007-11-20 |
Large Scale Biology Corporation |
Creation of variable length and sequence linker regions for dual-domain or multi-domain molecules
|
US7067111B1
(en)
*
|
1999-10-25 |
2006-06-27 |
Board Of Regents, University Of Texas System |
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
|
US20020028178A1
(en)
*
|
2000-07-12 |
2002-03-07 |
Nabil Hanna |
Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
US7018810B1
(en)
*
|
1999-12-07 |
2006-03-28 |
Amgen Inc. |
Chordin-like molecules and uses thereof
|
US20030023043A1
(en)
*
|
2000-03-02 |
2003-01-30 |
Kazuhisa Uchida |
Method of separating and purifying protein
|
WO2001070685A2
(en)
*
|
2000-03-22 |
2001-09-27 |
Solulink, Incorporated |
Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
|
EP1157999A1
(de)
*
|
2000-05-24 |
2001-11-28 |
Introgene B.V. |
Verfahren und Mitteln zur Verbesserung der Haut-Transplantation mittels Genabgabe-Vehikel mit Tropismus für primären Fibroblasten, sowie andere Verwendungsmöglichkeiten für diesen
|
WO2001092549A2
(en)
*
|
2000-05-31 |
2001-12-06 |
Genvec, Inc. |
Method and composition for targeting an adenoviral vector
|
CA2410906C
(en)
*
|
2000-06-02 |
2012-10-02 |
Board Of Regents, The University Of Texas System |
Ethylenedicysteine (ec)-drug conjugates
|
WO2001097858A2
(en)
*
|
2000-06-20 |
2001-12-27 |
Idec Pharmaceuticals Corporation |
Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
CA2422076A1
(en)
*
|
2000-09-18 |
2002-03-21 |
Idec Pharmaceutical Corporation |
Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
|
EP1322774A2
(de)
*
|
2000-09-20 |
2003-07-02 |
Crucell Holland B.V. |
Transduktion von dendritischen zellen durch verwendung der adenovirenvektoren
|
DE60138403D1
(de)
*
|
2000-09-26 |
2009-05-28 |
Crucell Holland Bv |
Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
|
EP1358344B1
(de)
*
|
2001-01-08 |
2007-08-29 |
Applera Corporation |
Dendritische chemilumineszierende Substrate
|
US20070065436A1
(en)
*
|
2001-01-31 |
2007-03-22 |
Biogen Idec Inc. |
Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
|
US20030103971A1
(en)
*
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
US20030211107A1
(en)
*
|
2002-01-31 |
2003-11-13 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US20020159996A1
(en)
*
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
JP2004533997A
(ja)
|
2001-02-20 |
2004-11-11 |
ザイモジェネティクス,インコーポレイティド |
Bcma及びtaciの両者を結合する抗体
|
EP1383920B1
(de)
*
|
2001-04-03 |
2010-09-29 |
Thermo Finnigan Llc |
Zur vereinfachung komplexer peptidgemische geeignete verfahren und kits
|
US20030003048A1
(en)
*
|
2001-04-26 |
2003-01-02 |
Chun Li |
Diagnostic imaging compositions, their methods of synthesis and use
|
WO2002087497A2
(en)
*
|
2001-04-26 |
2002-11-07 |
Board Of Regents, The University Of Texas System |
Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
ES2552281T3
(es)
|
2001-05-11 |
2015-11-26 |
Ludwig Institute For Cancer Research Ltd. |
Proteínas de unión específica y usos de las mismas
|
GB0112844D0
(en)
*
|
2001-05-25 |
2001-07-18 |
Psimei Pharmaceuticals Plc |
Neutron capture therapy
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7179617B2
(en)
*
|
2001-10-10 |
2007-02-20 |
Neose Technologies, Inc. |
Factor IX: remolding and glycoconjugation of Factor IX
|
US8008252B2
(en)
*
|
2001-10-10 |
2011-08-30 |
Novo Nordisk A/S |
Factor VII: remodeling and glycoconjugation of Factor VII
|
US7157277B2
(en)
|
2001-11-28 |
2007-01-02 |
Neose Technologies, Inc. |
Factor VIII remodeling and glycoconjugation of Factor VIII
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US7795210B2
(en)
*
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
US7696163B2
(en)
*
|
2001-10-10 |
2010-04-13 |
Novo Nordisk A/S |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US20050069962A1
(en)
*
|
2001-10-12 |
2005-03-31 |
Archer Robert M |
Antibody complexes and methods for immunolabeling
|
US8323903B2
(en)
*
|
2001-10-12 |
2012-12-04 |
Life Technologies Corporation |
Antibody complexes and methods for immunolabeling
|
US7261875B2
(en)
*
|
2001-12-21 |
2007-08-28 |
Board Of Regents, The University Of Texas System |
Dendritic poly (amino acid) carriers and methods of use
|
US20030135195A1
(en)
*
|
2002-01-16 |
2003-07-17 |
Oscar Jimenez |
Highly lubricious hydrophilic coating utilizing dendrimers
|
CA2476166C
(en)
*
|
2002-02-14 |
2011-11-15 |
Immunomedics, Inc. |
Anti-cd20 antibodies and fusion proteins thereof and methods of use
|
US8287864B2
(en)
*
|
2002-02-14 |
2012-10-16 |
Immunomedics, Inc. |
Structural variants of antibodies for improved therapeutic characteristics
|
US7282567B2
(en)
|
2002-06-14 |
2007-10-16 |
Immunomedics, Inc. |
Monoclonal antibody hPAM4
|
EP2865688A1
(de)
|
2002-03-01 |
2015-04-29 |
Immunomedics, Inc. |
Internalisierung von Anti-CD74-Antikörpern und Verfahren zur Verwendung
|
US8658773B2
(en)
|
2011-05-02 |
2014-02-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
DE60325184D1
(de)
|
2002-03-01 |
2009-01-22 |
Immunomedics Inc |
Rs7 antikörper
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
US20030180292A1
(en)
*
|
2002-03-14 |
2003-09-25 |
Idec Pharmaceuticals |
Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
|
WO2003079980A2
(en)
*
|
2002-03-19 |
2003-10-02 |
A & D Bioscience, Inc. |
Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
|
WO2003089603A2
(en)
|
2002-04-19 |
2003-10-30 |
Zymogenetics, Inc. |
Cytokine receptor
|
AU2003299509A1
(en)
*
|
2002-06-21 |
2004-05-13 |
University Of Utah Research Foundation |
Crosslinked compounds and methods of making and using thereof
|
DE60336555D1
(de)
|
2002-06-21 |
2011-05-12 |
Novo Nordisk Healthcare Ag |
Pegylierte glykoformen von faktor vii
|
EP1546203B1
(de)
*
|
2002-08-01 |
2012-06-20 |
Immunomedics, Inc. |
Alpha-fetoprotein-immu31-antikörper und fusionsproteine und verfahren zu deren anwendung
|
US7541440B2
(en)
|
2002-09-30 |
2009-06-02 |
Immunomedics, Inc. |
Chimeric, human and humanized anti-granulocyte antibodies and methods of use
|
US20060024289A1
(en)
*
|
2002-10-02 |
2006-02-02 |
Ruggles Sandra W |
Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
|
US7939304B2
(en)
*
|
2002-10-02 |
2011-05-10 |
Catalyst Biosciences, Inc. |
Mutant MT-SP1 proteases with altered substrate specificity or activity
|
CA2501616C
(en)
|
2002-10-08 |
2015-05-12 |
Immunomedics, Inc. |
Antibody therapy
|
CN101985443A
(zh)
*
|
2002-11-07 |
2011-03-16 |
得克萨斯大学体系董事会 |
乙二半胱氨酸(ec)-药物结合物、组合物及用于组织特异性疾病显像的方法
|
CN1787837A
(zh)
|
2002-11-15 |
2006-06-14 |
希龙公司 |
防止和治疗癌转移以及与癌转移相关的骨质损失的方法
|
US8420086B2
(en)
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
US7534427B2
(en)
*
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
KR20060003862A
(ko)
*
|
2003-03-14 |
2006-01-11 |
네오스 테크놀로지스, 인크. |
수용성분기폴리머 및 그 접합체
|
US20070026485A1
(en)
|
2003-04-09 |
2007-02-01 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
WO2006127896A2
(en)
*
|
2005-05-25 |
2006-11-30 |
Neose Technologies, Inc. |
Glycopegylated factor ix
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
US7932364B2
(en)
|
2003-05-09 |
2011-04-26 |
Novo Nordisk A/S |
Compositions and methods for the preparation of human growth hormone glycosylation mutants
|
PT1639011E
(pt)
*
|
2003-06-30 |
2009-01-20 |
Domantis Ltd |
Anticorpos (dab) de domínio único peguilados
|
WO2005012484A2
(en)
*
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
JP2007524649A
(ja)
*
|
2003-07-29 |
2007-08-30 |
イミューノメディクス、インコーポレイテッド |
フッ素化炭水化物複合体
|
US7109304B2
(en)
|
2003-07-31 |
2006-09-19 |
Immunomedics, Inc. |
Humanized anti-CD19 antibodies
|
US7083936B2
(en)
*
|
2003-08-01 |
2006-08-01 |
Beckman Coulter, Inc. |
Aminodextran compositions and conjugates and method of making and using them
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
US20080305992A1
(en)
*
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
US7956032B2
(en)
*
|
2003-12-03 |
2011-06-07 |
Novo Nordisk A/S |
Glycopegylated granulocyte colony stimulating factor
|
US20060040856A1
(en)
*
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
US20080318850A1
(en)
*
|
2003-12-03 |
2008-12-25 |
Neose Technologies, Inc. |
Glycopegylated Factor Ix
|
US9050378B2
(en)
*
|
2003-12-10 |
2015-06-09 |
Board Of Regents, The University Of Texas System |
N2S2 chelate-targeting ligand conjugates
|
DK1704166T3
(en)
|
2004-01-07 |
2015-06-01 |
Novartis Vaccines & Diagnostic |
M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF
|
KR101439880B1
(ko)
|
2004-01-08 |
2014-09-12 |
라티오팜 게엠베하 |
펩티드의 오-결합형 글리코실화
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
US20110171126A1
(en)
*
|
2010-01-11 |
2011-07-14 |
Center For Molecular Medicine And Immunology |
Enhanced Cytotoxicity of Anti-CD74 and Anti-HLA-DR Antibodies with Interferon-Gamma
|
US8883160B2
(en)
*
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
KR101347613B1
(ko)
|
2004-03-31 |
2014-01-06 |
다나-파버 캔서 인스티튜트 인크. |
암에 걸린 인간 환자의 표피성장인자 수용체 표적 치료의 유효 가능성 결정 방법, 키트, 핵산 프로브 및 프라이머쌍
|
SE0400886D0
(sv)
*
|
2004-04-02 |
2004-04-02 |
Amersham Biosciences Ab |
Process of purification
|
ES2640284T3
(es)
*
|
2004-04-12 |
2017-11-02 |
Catalyst Biosciences, Inc. |
Polipéptidos MT-SP1 mutantes
|
CN1296711C
(zh)
*
|
2004-05-14 |
2007-01-24 |
沈阳迈迪生物医学技术有限公司 |
乳腺癌的Her-2免疫组织化学诊断试剂盒
|
EP1771066A2
(de)
|
2004-07-13 |
2007-04-11 |
Neose Technologies, Inc. |
Remodellierung von verzweigtem peg und klykolysierung von glucagonähnlichem peptide-1 glp-1
|
US8268967B2
(en)
|
2004-09-10 |
2012-09-18 |
Novo Nordisk A/S |
Glycopegylated interferon α
|
ES2572779T3
(es)
|
2004-10-29 |
2016-06-02 |
Ratiopharm Gmbh |
Remodelación y glucopegilación del Factor de Crecimiento de Fibroblastos (FGF)
|
JP2008526864A
(ja)
*
|
2005-01-06 |
2008-07-24 |
ネオス テクノロジーズ インコーポレイテッド |
糖断片を用いる糖結合
|
ES2449195T3
(es)
|
2005-01-10 |
2014-03-18 |
Ratiopharm Gmbh |
Factor estimulante de colonias de granulocitos glicopegilado
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
EP3332808B1
(de)
|
2005-03-03 |
2020-09-09 |
Immunomedics Inc. |
Humanisierte l243-antikörper
|
US20060246544A1
(en)
*
|
2005-03-30 |
2006-11-02 |
Neose Technologies,Inc. |
Manufacturing process for the production of peptides grown in insect cell lines
|
US8067006B2
(en)
*
|
2005-04-06 |
2011-11-29 |
Immunomedics, Inc. |
Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
EP2386571B1
(de)
|
2005-04-08 |
2016-06-01 |
ratiopharm GmbH |
Zusammensetzungen und Verfahren zur Herstellung von Glycosylierungsmutanten eines Proteaseresistenten menschlichen Wachstumshormons
|
EP1888098A2
(de)
*
|
2005-05-25 |
2008-02-20 |
Neose Technologies, Inc. |
Glykopegylierte erythropoetin-formulierungen
|
US20110003744A1
(en)
*
|
2005-05-25 |
2011-01-06 |
Novo Nordisk A/S |
Glycopegylated Erythropoietin Formulations
|
JP5457671B2
(ja)
*
|
2005-07-28 |
2014-04-02 |
ノバルティス アーゲー |
M−csf特異的モノクローナル抗体およびその使用
|
US20070105755A1
(en)
*
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
US8097237B2
(en)
|
2005-08-23 |
2012-01-17 |
Stc.Unm |
Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma
|
JP4808453B2
(ja)
*
|
2005-08-26 |
2011-11-02 |
株式会社荏原製作所 |
研磨方法及び研磨装置
|
WO2007026972A2
(en)
*
|
2005-09-01 |
2007-03-08 |
Canon Kabushiki Kaisha |
Binding protein molecule
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
RS52004B
(en)
*
|
2005-12-12 |
2012-04-30 |
F. Hoffmann-La Roche Ag |
ANTIBODIES AGAINST AMYLOID BETA WITH GLYCOSILATION IN THE VARIABLE REGION
|
EP2674440B1
(de)
|
2005-12-16 |
2019-07-03 |
IBC Pharmaceuticals, Inc. |
Polyvalente bioaktive anordnungen auf immunglobulinbasis
|
US8758723B2
(en)
|
2006-04-19 |
2014-06-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for cellular imaging and therapy
|
TWI369402B
(en)
|
2006-07-05 |
2012-08-01 |
Catalyst Biosciences Inc |
Protease screening methods and proteases identified thereby
|
US9187532B2
(en)
|
2006-07-21 |
2015-11-17 |
Novo Nordisk A/S |
Glycosylation of peptides via O-linked glycosylation sequences
|
CA2659820A1
(en)
|
2006-08-04 |
2008-02-14 |
Novartis Ag |
Ephb3-specific antibody and uses thereof
|
GEP20125612B
(en)
|
2006-08-18 |
2012-08-27 |
Novartis Ag |
Prlr-specific antibody and usage thereof
|
US20080095414A1
(en)
*
|
2006-09-12 |
2008-04-24 |
Vladimir Desh |
Correction of functional nuclear imaging data for motion artifacts using anatomical data
|
EP2054521A4
(de)
*
|
2006-10-03 |
2012-12-19 |
Novo Nordisk As |
Verfahren zur reinigung von polypeptid-konjugate
|
US10925977B2
(en)
|
2006-10-05 |
2021-02-23 |
Ceil>Point, LLC |
Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
|
WO2008070780A1
(en)
|
2006-12-07 |
2008-06-12 |
Novartis Ag |
Antagonist antibodies against ephb3
|
US9090693B2
(en)
|
2007-01-25 |
2015-07-28 |
Dana-Farber Cancer Institute |
Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
|
MX2009009782A
(es)
|
2007-03-15 |
2010-09-10 |
Ludwig Inst Cancer Res |
Metodo de tratamiento que utiliza anticuerpos egfr e inhibidores de src y formulaciones relacionadas.
|
CA2682897C
(en)
|
2007-04-03 |
2016-11-22 |
Biogenerix Ag |
Methods of treatment using glycopegylated g-csf
|
EP2465541B1
(de)
*
|
2007-05-22 |
2018-07-18 |
Wyeth LLC |
Verbesserte Verfahren zur Herstellung von Hydraziden
|
AU2014208212B2
(en)
*
|
2007-05-22 |
2016-07-28 |
Wyeth |
Improved processes for making hydrazides
|
CN101778859B
(zh)
|
2007-06-12 |
2014-03-26 |
诺和诺德公司 |
改良的用于生产核苷酸糖的方法
|
WO2009023265A1
(en)
|
2007-08-14 |
2009-02-19 |
Ludwig Institute For Cancer Research |
Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof
|
US8207112B2
(en)
|
2007-08-29 |
2012-06-26 |
Biogenerix Ag |
Liquid formulation of G-CSF conjugate
|
EP2242514B1
(de)
*
|
2008-01-30 |
2015-09-30 |
University Of Kansas |
Wirkstoffträger für intralymphatische chemotherapie
|
US20130189239A1
(en)
|
2008-02-27 |
2013-07-25 |
Novo Nordisk A/S |
Conjugated Factor VIII Molecules
|
NZ590330A
(en)
*
|
2008-07-21 |
2012-08-31 |
Immunomedics Inc |
Structural variants of anti-cd20 antibodies for improved therapeutic characteristics
|
EP3243527B1
(de)
|
2009-02-13 |
2019-06-05 |
Immunomedics, Inc. |
Immunkonjugate mit einem intrazellulär spaltbaren linker
|
US8614185B2
(en)
*
|
2009-05-04 |
2013-12-24 |
Centocor Ortho Biotech Inc. |
Fusion proteins of alpha-MSH derivatives and Fc
|
CA2774260C
(en)
|
2009-09-16 |
2018-10-09 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
TW201120210A
(en)
|
2009-11-05 |
2011-06-16 |
Hoffmann La Roche |
Glycosylated repeat-motif-molecule conjugates
|
EP2506881B1
(de)
|
2009-12-02 |
2024-03-06 |
Immunomedics, Inc. |
Kombination aus radioimmuntherapie und antikörper-arznei-konjugaten für verbesserte krebstherapie
|
EP2603528B1
(de)
|
2010-08-10 |
2016-10-12 |
Glycotope GmbH |
Fab-glykosylierte antikörper
|
US8956859B1
(en)
|
2010-08-13 |
2015-02-17 |
Aviex Technologies Llc |
Compositions and methods for determining successful immunization by one or more vaccines
|
US10865383B2
(en)
|
2011-07-12 |
2020-12-15 |
Lineage Cell Therapeutics, Inc. |
Methods and formulations for orthopedic cell therapy
|
CA2853138A1
(en)
|
2011-12-05 |
2013-06-13 |
Immunomedics, Inc. |
Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
WO2013096455A1
(en)
|
2011-12-20 |
2013-06-27 |
Dana-Farber Cancer Institute, Inc. |
Methods for diagnosing and treating oncogenic kras-associated cancer
|
CA2874521A1
(en)
|
2012-05-24 |
2013-11-28 |
Dana-Farber Cancer Institute, Inc. |
Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer
|
US20150285802A1
(en)
|
2012-07-18 |
2015-10-08 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating, preventing and predicting risk of developing breast cancer
|
US9315567B2
(en)
|
2012-08-14 |
2016-04-19 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
HRP20220399T1
(hr)
|
2012-12-13 |
2022-05-13 |
Immunomedics, Inc. |
Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
US9107960B2
(en)
|
2012-12-13 |
2015-08-18 |
Immunimedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
ES2759503T3
(es)
|
2013-05-02 |
2020-05-11 |
Glykos Finland Oy |
Conjugados de una glicoproteína o un glicano con una carga útil tóxica
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
RU2699289C2
(ru)
|
2013-08-26 |
2019-09-04 |
Байонтек Рисерч Энд Дивелопмент, Инк. |
НУКЛЕИНОВЫЕ КИСЛОТЫ, КОДИРУЮЩИЕ АНТИТЕЛА ПРОТИВ СИАЛИРОВАННОГО АНТИГЕНА ЛЬЮИСАа ЧЕЛОВЕКА
|
WO2015050844A1
(en)
|
2013-10-01 |
2015-04-09 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating cancer with atovaquone-related compounds
|
MX2016010683A
(es)
|
2014-02-21 |
2017-05-11 |
Ibc Pharmaceuticals Inc |
Terapia para tratar enfermedades mediante la induccion de respuesta inmune de las células que expresan trop-2.
|
CN106029098A
(zh)
|
2014-02-25 |
2016-10-12 |
免疫医疗公司 |
人源化rfb4抗cd22抗体
|
WO2015149006A2
(en)
|
2014-03-27 |
2015-10-01 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin
|
PT3154583T
(pt)
|
2014-06-04 |
2021-03-24 |
Biontech Res And Development Inc |
Anticorpos monoclonais humanos para o gangliósido gd2
|
US9580495B2
(en)
|
2014-06-24 |
2017-02-28 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
WO2015197919A1
(en)
|
2014-06-25 |
2015-12-30 |
Glykos Finland Oy |
Antibody drug conjugates binding to high-mannose n-glycan
|
EP3160513B1
(de)
|
2014-06-30 |
2020-02-12 |
Glykos Finland Oy |
Saccharidderivat einer toxischen nutzlast und antikörperkonjugate davon
|
CN106999517A
(zh)
|
2014-10-07 |
2017-08-01 |
免疫医疗公司 |
抗体‑药物缀合物的新辅助剂用途
|
EP3286224A4
(de)
|
2015-04-22 |
2018-11-14 |
Immunomedics, Inc. |
Isolierung, detektion, diagnose und/oder charakterisierung von zirkulierenden trop-2-positiven krebszellen
|
DK3313879T3
(da)
|
2015-06-24 |
2022-03-14 |
Hoffmann La Roche |
Anti-transferrinreceptor-antistoffer med tilpasset affinitet
|
WO2016210108A1
(en)
|
2015-06-25 |
2016-12-29 |
Immunomedics, Inc. |
Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
SI3316885T1
(sl)
|
2015-07-01 |
2021-09-30 |
Immunomedics, Inc. |
Imunokonjugati protitelo-SN-38 z linkerjem CL2A
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
CN114014936A
(zh)
|
2015-10-02 |
2022-02-08 |
豪夫迈·罗氏有限公司 |
双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
|
CA3011372A1
(en)
|
2016-02-10 |
2017-08-17 |
Immunomedics, Inc. |
Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
|
WO2017189279A1
(en)
|
2016-04-27 |
2017-11-02 |
Immunomedics, Inc. |
Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
|
CA3026490A1
(en)
|
2016-06-09 |
2017-12-14 |
University Of Leicester |
Monoclonal antibodies, compositions and methods for detecting mucin-like protein (mlp) as a biomarker for ovarian and pancreatic cancer
|
WO2018183041A1
(en)
|
2017-03-27 |
2018-10-04 |
Immunomedics, Inc. |
Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor
|
EP3606964A4
(de)
|
2017-04-03 |
2020-12-09 |
Immunomedics, Inc. |
Subkutane verabreichung von antikörper-arzneimittelkonjugaten zur krebstherapie
|
WO2018206734A1
(en)
*
|
2017-05-11 |
2018-11-15 |
Vib Vzw |
Glycosylation of variable immunoglobulin domains
|
US11707522B2
(en)
|
2017-10-13 |
2023-07-25 |
Boehringer Ingelheim International Gmbh |
Human antibodies to Tn antigen
|
EP3794041B1
(de)
|
2018-05-18 |
2023-07-12 |
Glycotope GmbH |
Anti-muc1-antikörper
|
CN109270064B
(zh)
*
|
2018-11-12 |
2020-12-01 |
新乡医学院 |
一种基于葡聚糖微球的免疫沉淀试剂及其制备方法与应用
|
KR20220004979A
(ko)
|
2019-03-27 |
2022-01-12 |
유엠씨 우트레크트 홀딩 비.브이. |
조작된 iga 항체 및 사용 방법
|
EP4326314A2
(de)
*
|
2021-04-23 |
2024-02-28 |
University of Maryland, College Park |
Fc-glycan-remodellierung für ortsspezifische antikörperkonjugation und anwendungen davon
|
EP4342497A1
(de)
|
2021-05-10 |
2024-03-27 |
Kawasaki Institute of Industrial Promotion |
Antikörper mit reduzierter bindungsaffinität für antigen
|